JP2016514148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514148A5 JP2016514148A5 JP2016501850A JP2016501850A JP2016514148A5 JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5 JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778540P | 2013-03-13 | 2013-03-13 | |
| US61/778,540 | 2013-03-13 | ||
| US201361808381P | 2013-04-04 | 2013-04-04 | |
| US61/808,381 | 2013-04-04 | ||
| PCT/US2014/025441 WO2014159911A1 (en) | 2013-03-13 | 2014-03-13 | Compositions comprising anti-cd38 antibodies and carfilzomib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514148A JP2016514148A (ja) | 2016-05-19 |
| JP2016514148A5 true JP2016514148A5 (cg-RX-API-DMAC7.html) | 2017-06-15 |
| JP6279065B2 JP6279065B2 (ja) | 2018-02-14 |
Family
ID=51625288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501850A Active JP6279065B2 (ja) | 2013-03-13 | 2014-03-13 | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160022813A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2968555B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6279065B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210043006A (cg-RX-API-DMAC7.html) |
| CN (3) | CN105407921A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014244333B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2904630A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2808565T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL292978A (cg-RX-API-DMAC7.html) |
| MX (1) | MX373308B (cg-RX-API-DMAC7.html) |
| MY (1) | MY175418A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2968555T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2968555T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2670127C2 (cg-RX-API-DMAC7.html) |
| SG (3) | SG11201506956TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014159911A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201507310B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| SG11201502163QA (en) | 2012-09-25 | 2015-04-29 | Morphosys Ag | Combinations and uses thereof |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3820575A1 (en) * | 2018-07-10 | 2021-05-19 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| AU2020397170A1 (en) | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| TWI887310B (zh) * | 2019-12-06 | 2025-06-21 | 美商賽諾菲 安萬特美國有限責任公司 | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20070042436A1 (en) * | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| RU2402568C2 (ru) * | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| DK1745064T3 (da) | 2004-04-15 | 2011-04-11 | Proteolix Inc | Forbindelser til proteasomenzyminhibering |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| ES2408216T3 (es) | 2004-12-07 | 2013-06-19 | Onyx Therapeutics, Inc. | Composición para la inhibición del proteasoma |
| MX2007009940A (es) * | 2005-02-18 | 2007-10-10 | Medarex Inc | Anticuerpos monoclonales que carecen de residuos fucosilo contra cd30. |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| CN101534860B (zh) * | 2006-08-07 | 2013-03-27 | 艾伯特生物治疗学公司 | 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法 |
| RU2456990C2 (ru) * | 2006-09-15 | 2012-07-27 | Янссен Фармацевтика Нв | Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2727278A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| AU2009308516B2 (en) * | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| EP2355828B1 (en) * | 2008-11-13 | 2018-05-30 | Gilead Calistoga LLC | Therapies for hematologic malignancies |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| JP2012526079A (ja) * | 2009-05-06 | 2012-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体の使用 |
| KR101912957B1 (ko) * | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| WO2012135528A2 (en) * | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
-
2014
- 2014-03-13 ES ES14773270T patent/ES2808565T3/es active Active
- 2014-03-13 PT PT147732705T patent/PT2968555T/pt unknown
- 2014-03-13 KR KR1020217010487A patent/KR20210043006A/ko not_active Ceased
- 2014-03-13 SG SG11201506956TA patent/SG11201506956TA/en unknown
- 2014-03-13 MY MYPI2015702949A patent/MY175418A/en unknown
- 2014-03-13 US US14/775,641 patent/US20160022813A1/en not_active Abandoned
- 2014-03-13 CN CN201480024843.3A patent/CN105407921A/zh active Pending
- 2014-03-13 JP JP2016501850A patent/JP6279065B2/ja active Active
- 2014-03-13 RU RU2015143462A patent/RU2670127C2/ru active
- 2014-03-13 SG SG10201913777XA patent/SG10201913777XA/en unknown
- 2014-03-13 CN CN202510798995.9A patent/CN120860201A/zh active Pending
- 2014-03-13 EP EP14773270.5A patent/EP2968555B1/en active Active
- 2014-03-13 CN CN202010773679.3A patent/CN112043826A/zh active Pending
- 2014-03-13 IL IL292978A patent/IL292978A/en unknown
- 2014-03-13 KR KR1020157027249A patent/KR102241868B1/ko active Active
- 2014-03-13 EP EP20180210.5A patent/EP3769783A1/en not_active Withdrawn
- 2014-03-13 CA CA2904630A patent/CA2904630A1/en not_active Abandoned
- 2014-03-13 PL PL14773270T patent/PL2968555T3/pl unknown
- 2014-03-13 WO PCT/US2014/025441 patent/WO2014159911A1/en not_active Ceased
- 2014-03-13 AU AU2014244333A patent/AU2014244333B2/en active Active
- 2014-03-13 RU RU2018134595A patent/RU2723937C2/ru active
- 2014-03-13 IL IL241407A patent/IL241407B/en unknown
- 2014-03-13 MX MX2015012297A patent/MX373308B/es active IP Right Grant
- 2014-03-13 SG SG10201707464SA patent/SG10201707464SA/en unknown
-
2015
- 2015-10-01 ZA ZA2015/07310A patent/ZA201507310B/en unknown
-
2016
- 2016-12-22 US US15/389,279 patent/US20170106085A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,693 patent/US20190321471A1/en not_active Abandoned
-
2021
- 2021-05-19 US US17/324,478 patent/US20220088194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514148A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506388A5 (cg-RX-API-DMAC7.html) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| JP2016536314A5 (cg-RX-API-DMAC7.html) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| NZ607473A (en) | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| JP2017528462A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191115T1 (hr) | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora | |
| JP2012136541A5 (cg-RX-API-DMAC7.html) | ||
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2020502198A5 (cg-RX-API-DMAC7.html) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| CO2018005983A2 (es) | Compuestos de isoindol | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| RU2010103781A (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| JP2020533383A5 (cg-RX-API-DMAC7.html) | ||
| JP2020533382A5 (cg-RX-API-DMAC7.html) |